|
Jul 30
|
PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025
|
|
Jul 16
|
PYPD: Positive Topline Data From D-PLEX₁₀₀ Trial Contributes to Multiple Subsequent Benefits
|
|
Jul 15
|
Finance Herald Publishes Coverage of PolyPid's Groundbreaking New 60-Day GLP-1 Delivery Tech
|
|
Jul 15
|
PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market
|
|
Jun 22
|
Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks
|
|
Jun 16
|
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
|
|
May 15
|
PolyPid Ltd (PYPD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
|
|
May 14
|
PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results
|
|
Mar 11
|
PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
|
|
Feb 13
|
PolyPid Ltd (PYPD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising R&D Costs
|
|
Feb 12
|
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
|
|
Oct 1
|
PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
|
|
Jul 31
|
PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024
|
|
Jun 18
|
PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial
|
|
May 10
|
PolyPid Ltd. (NASDAQ:PYPD) Q1 2024 Earnings Call Transcript
|
|
May 8
|
PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results
|
|
May 1
|
PolyPid to Participate in Citizens JMP Life Sciences Conference
|
|
Apr 30
|
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
|
|
Apr 24
|
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024
|
|
Apr 24
|
PYPD: Polypid is Enhancing Surgical Outcomes
|